Changeflow GovPing Healthcare & Life Sciences Otsuka Injectable Preparation, European Patent ...
Routine Notice Added Final

Otsuka Injectable Preparation, European Patent EP3539534A1

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

European Patent Office published application EP3539534A1 for Otsuka Pharmaceutical Co., Ltd. on April 15, 2026. The injectable preparation patent covers therapeutic applications classified under A61P 25/18 (psychiatric disorders) and A61P 25/24 (neurological conditions), designated across all EU member states including Germany, France, and the United Kingdom.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 17 changes logged to date.

What changed

European Patent Office published patent application EP3539534A1 for Otsuka Pharmaceutical Co., Ltd., covering an injectable preparation with therapeutic applications in psychiatric disorders (A61P 25/18) and neurological conditions (A61P 25/24). The application was filed with search report and is designated across all EU member states.

Pharmaceutical manufacturers and investors in CNS therapeutic development should note the IPC classifications A61K 31/496 (pipecolic acid derivatives) combined with A61K 9/06 (injectable preparations), which define the formulation and therapeutic scope. Patent grants provide market exclusivity within designated territories for the 20-year term from filing.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

INJECTABLE PREPARATION

Publication EP3539534A1 Kind: A1 Apr 15, 2026

Applicants

Otsuka Pharmaceutical Co., Ltd.

Inventors

Kaneko, Daiki, Matsuda, Takakuni, Hoshika, Yusuke

IPC Classifications

A61K 9/06 20060101AFI20190814BHEP A61K 47/10 20170101ALI20190814BHEP A61K 47/32 20060101ALI20190814BHEP A61K 47/38 20060101ALI20190814BHEP A61K 31/496 20060101ALI20190814BHEP A61P 25/18 20060101ALI20190814BHEP A61P 25/24 20060101ALI20190814BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Intellectual property registration Therapeutic formulation
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
GxP
Topics
Public Health

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!